New drug aims to stop cancer wasting
NCT ID NCT07168226
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests a drug called ASCA101 in 135 adults with solid tumors (colorectal, ovarian, or lung cancer) who have cachexia—a condition causing severe weight loss and muscle wasting. Participants receive either ASCA101, an active control (Megace), or a placebo for 12 weeks. The main goal is to see if ASCA101 helps increase or maintain body weight compared to baseline.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASCA101
What this could lead to
If it works, this could lead to a new treatment that helps cancer patients with cachexia maintain or gain weight, improving their strength and quality of life.
What could go wrong
This is an early Phase 2 trial with only 135 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight improvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ajou University Hospital
RECRUITINGGyeonggi-do, Suwon-si, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Chung-Ang University Gwangmyeong Hospital
RECRUITINGGyeonggi-do, Gwangmyeong-si, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Korea University Anam Hospital
RECRUITINGSeoul, Seongbuk-gu, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
National Cancer Center
RECRUITINGGyeonggi-do, Goyang-si, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Samsung Medical Center
RECRUITINGSeoul, Gangnam-gu, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Seoul ST. Mary's hospital
RECRUITINGSeoul, Seocho-gu, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact